Kathmere Capital Management LLC bought a new position in shares of Enovix Corporation (NASDAQ:ENVX - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 24,820 shares of the company's stock, valued at approximately $182,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. Bank of New York Mellon Corp raised its stake in Enovix by 6.1% during the 4th quarter. Bank of New York Mellon Corp now owns 501,539 shares of the company's stock worth $5,452,000 after buying an additional 28,905 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Enovix by 9.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,348,340 shares of the company's stock worth $14,656,000 after purchasing an additional 119,288 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of Enovix by 6.8% during the 4th quarter. Victory Capital Management Inc. now owns 19,695 shares of the company's stock valued at $214,000 after purchasing an additional 1,257 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Enovix in the 4th quarter valued at approximately $3,484,000. Finally, Amundi grew its position in shares of Enovix by 360.8% in the 4th quarter. Amundi now owns 235,369 shares of the company's stock valued at $2,558,000 after purchasing an additional 184,294 shares during the period. 50.92% of the stock is owned by institutional investors.
Analyst Ratings Changes
ENVX has been the topic of a number of research reports. TD Securities cut their price target on shares of Enovix from $10.00 to $7.00 and set a "hold" rating on the stock in a research note on Thursday, May 1st. B. Riley restated a "buy" rating and set a $17.00 price objective (up from $12.00) on shares of Enovix in a report on Thursday. Craig Hallum reaffirmed a "buy" rating and issued a $15.00 price objective (up from $12.00) on shares of Enovix in a research report on Tuesday, July 8th. JPMorgan Chase & Co. lowered their target price on Enovix from $10.00 to $9.00 and set an "overweight" rating for the company in a report on Thursday, May 1st. Finally, Cowen reissued a "hold" rating on shares of Enovix in a research note on Tuesday, July 8th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.55.
Check Out Our Latest Stock Analysis on ENVX
Enovix Price Performance
Shares of NASDAQ ENVX opened at $14.65 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 4.68 and a quick ratio of 4.49. The business has a 50-day moving average of $9.04 and a 200-day moving average of $9.10. The stock has a market capitalization of $2.81 billion, a price-to-earnings ratio of -11.36 and a beta of 2.09. Enovix Corporation has a fifty-two week low of $5.27 and a fifty-two week high of $18.68.
Enovix declared that its board has authorized a stock buyback program on Wednesday, July 2nd that authorizes the company to buyback $60.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 3.1% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's leadership believes its shares are undervalued.
Enovix Profile
(
Free Report)
Enovix Corporation designs develops and manufactures silicon-anode lithium-ion batteries. It serves wearables and IoT, smartphone, laptops and tablets, industrial and medical, and electric vehicles industries. The company was founded in 2007 and is headquartered in Fremont, California.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enovix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovix wasn't on the list.
While Enovix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.